Kao W, McGee D, Liao Y, Heroux A L, Mullen G M, Johnson M R, Costanzo M R
Loyola University Medical Center, Maywood, Illinois.
J Am Coll Cardiol. 1994 Nov 15;24(6):1547-51. doi: 10.1016/0735-1097(94)90153-8.
This study compared the survival of patients with heart failure who have waited > 6 months for heart transplantation with that patients who undergo heart transplantation after a similarly prolonged waiting period.
There are little data describing outcome in patients with severe heart failure who have waited for extended periods of time on the heart transplant waiting list.
Sixty-three consecutive patients who spent > 6 months on the heart transplant waiting list were examined. Mean (+/- SD) age was 53 +/- 9 years, mean left ventricular ejection fraction was 19 +/- 6%, and all were taking digoxin and diuretic and vasodilator agents. Patients who underwent transplantation during the follow-up period were censored from the pretransplantation analysis, and their survival was examined as part of the posttransplantation phase of the study.
Of the 63 original patients examined, 25 underwent transplantation, 10 during inotropic or mechanical circulatory support. The pretransplantation mortality rate was 6% at 6 months after the 6-month milestone on the waiting list, 12% at 12 months and 22% at 18 months. The posttransplantation mortality rate was 5% at 6 months, 10% at 12 months and 24% at 18 months. There were no differences in survival at any time between the two phases of the study.
Survival of patients who have survived > 6 months on the heart transplant waiting list is generally good. Although heart transplantation did not appear to confer additional survival advantage over medical therapy, a large proportion of the patients who underwent transplantation were critically ill at the time of transplantation and would undoubtedly have died of progressive heart failure had they not undergone transplantation. We conclude that heart transplantation should still be considered a therapeutic alternative in patients with heart failure even after a prolonged waiting period on the heart transplant waiting list.
本研究比较了等待心脏移植超过6个月的心力衰竭患者与在类似延长等待期后接受心脏移植的患者的生存率。
关于在心脏移植等待名单上等待较长时间的重度心力衰竭患者的预后数据很少。
对63例在心脏移植等待名单上度过超过6个月的连续患者进行了检查。平均(±标准差)年龄为53±9岁,平均左心室射血分数为19±6%,所有患者均服用地高辛、利尿剂和血管扩张剂。在随访期间接受移植的患者在移植前分析中被剔除,其生存率作为研究移植后阶段的一部分进行检查。
在最初检查的63例患者中,25例接受了移植,其中10例在使用正性肌力药物或机械循环支持期间接受移植。在等待名单上达到6个月里程碑后的6个月时,移植前死亡率为6%,12个月时为12%,18个月时为22%。移植后死亡率在6个月时为5%,12个月时为10%,18个月时为24%。研究的两个阶段在任何时间的生存率均无差异。
在心脏移植等待名单上存活超过6个月的患者生存率总体良好。虽然心脏移植似乎没有比药物治疗带来额外的生存优势,但很大一部分接受移植的患者在移植时病情危急,如果不进行移植,无疑会死于进行性心力衰竭。我们得出结论,即使在心脏移植等待名单上经过长时间等待后,心脏移植仍应被视为心力衰竭患者的一种治疗选择。